TGFBR2 KO CAR27/IL-15 NK cells

DRUG4 trials

Sponsors

M.D. Anderson Cancer Center

Conditions

Gastric Cancer, MetastaticHodgkin LymphomaLymphoidMyeloid MalignanciesPancreatic Cancer

Phase 1

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

RecruitingNCT06930651

M.D. Anderson Cancer CenterMyeloid Malignancies

Start: 2025-09-03End: 2030-05-01Target: 42Updated: 2026-03-11

Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

Not yet recruitingNCT07377526

M.D. Anderson Cancer CenterPancreatic Cancer

Start: 2026-07-01End: 2030-03-01Target: 37Updated: 2026-01-30

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

Not yet recruitingNCT07444632

M.D. Anderson Cancer CenterHodgkin Lymphoma, Lymphoid

Start: 2026-08-31End: 2032-09-30Target: 60Updated: 2026-03-27

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

Not yet recruitingNCT07509008

M.D. Anderson Cancer CenterGastric Cancer, Metastatic

Start: 2026-09-01End: 2030-07-01Target: 10Updated: 2026-04-03